Dihydrocodeine is an opioid medicine used for pain. It can cause sedation, respiratory depression, tolerance and physical dependence. Some people develop opioid addiction, a separate clinical condition based on impaired control, craving, continued use despite harm and related features. Prescribed use and physical dependence do not by themselves establish addiction.
The risks of misuse, dependence, addiction and overdose should be discussed when dihydrocodeine is prescribed. Individual risk varies, and unsupported rankings or prescribing trends should not be used to predict what will happen to a particular patient.
In the UK, dihydrocodeine is one of several opioid medicines used for pain. Approved indications and formulations vary by product; the current product information and the prescriber’s instructions determine how it should be used.
Prescription and non-medical opioid use are different contexts. This article focuses on dihydrocodeine safety, signs of opioid use disorder, overdose response and evidence-based treatment without assuming that prescribed use inevitably becomes misuse.
UK regulators warn that prolonged opioid use can lead to tolerance, dependence and addiction even at therapeutic doses. Prescribers should agree treatment goals, review benefit and harm, and plan how treatment will end.
Dihydrocodeine acts at opioid receptors to reduce pain and can also cause drowsiness or euphoria. Repeated use may produce tolerance and physical dependence. Opioid use disorder is diagnosed from a broader pattern such as impaired control, craving and continued use despite harm, not from one effect or symptom alone.
Prescribed treatment does not automatically progress from tolerance to dependence and then addiction. Dihydrocodeine is not the only prescription opioid in the UK. Some pharmacy products contain low-dose dihydrocodeine combined with another medicine, but availability and limits depend on the authorized product and current UK rules.
Some people take more dihydrocodeine than prescribed, use it for non-medical reasons or combine it with other substances. These patterns increase risk, but they should not be assumed for every patient. Any loss of control, craving, continued use despite harm or unsafe combination use warrants assessment.
What Is Dihydrocodeine: Medical Uses And Prescriptions
Dihydrocodeine is a semi-synthetic opioid created from codeine. According to Cancer Research UK, it is available in different forms, such as tablets, capsules and liquid formulations, and is usually prescribed to manage moderate to severe pain.
Dihydrocodeine may be prescribed when an opioid is considered appropriate for pain, but the indication, formulation and duration depend on the authorized product and individual clinical circumstances. Benefits and harms should be reviewed, especially during longer-term treatment.
Why Is Dihydrocodeine Addictive
Dihydrocodeine acts mainly at opioid receptors, altering pain signaling and potentially producing sedation or euphoria. Tolerance may develop with repeated use, but dose increases should only follow clinical review because higher exposure can increase adverse effects and overdose risk.
Physical dependence means withdrawal can occur after abrupt reduction or stopping; it is not the same as addiction. Opioid use disorder involves impaired control, craving and continued use despite harm. Either concern should be discussed without stigma with a qualified clinician.
People should receive clear information about dependence, addiction, overdose and withdrawal risks before and during treatment. Not everyone taking dihydrocodeine develops physical dependence or opioid use disorder. If dependence has developed, abrupt stopping can cause withdrawal and an individual reduction plan may be needed.
Non-Medical Dihydrocodeine Use and Overdose Risk
Non-medical use includes taking dihydrocodeine in a way other than prescribed, using someone else’s medicine or seeking intoxication. Risk rises with larger or unpredictable amounts, reduced tolerance, unknown products and combination with alcohol, benzodiazepines, gabapentinoids or other sedatives. Any opioid can cause fatal respiratory depression.
Dihydrocodeine And Alcohol: The Risk Of Mixing Substances
One of the particularly dangerous practices related to the recreational use of dihydrocodeine is mixing it with alcohol. Dihydrocodeine and alcohol both impair the central nervous system. Combining them can cause profound sedation, respiratory depression, coma and death. The risk is unpredictable, so alcohol should be avoided unless the prescriber or pharmacist has specifically advised otherwise.
How Long Does Dihydrocodeine Stay In Your System
How long effects and detectable drug or metabolites persist varies by formulation, dose, metabolism, organ function and the test used. A perceived “crash” does not itself explain addiction; repeated dosing to avoid withdrawal may indicate physical dependence and should prompt clinical review.
Repeated use to relieve withdrawal can reinforce continued use, but opioid use disorder is assessed from the full pattern of symptoms and harms rather than a single cycle.
Like other opioids, dihydrocodeine, when taken as prescribed, can bring about several side effects. Common physical side effects include [3]:
- Drowsiness and dizziness
- Nausea and vomiting
- Typical opioid side effect: constipation.
- Headaches
- Dry mouth
Side effects can become more severe with higher exposure or combination with other sedatives. Drowsiness and dizziness can impair driving, work and other activities requiring alertness; follow the product warning and clinical advice.
Serious Dihydrocodeine Effects and Overdose Risk
Serious effects can occur with any formulation when too much is taken, tolerance is reduced or dihydrocodeine is combined with alcohol or other sedatives. Risk cannot be inferred from tablet strength alone.
These include:
- Respiratory depression (slow and shallow breathing)
- Extreme drowsiness and confusion
- In severe cases, loss of consciousness or coma may occur.
- Increased overdose risk with alcohol, benzodiazepines, gabapentinoids or other sedatives
Mood, sleep and cognition may be affected by dihydrocodeine, withdrawal, pain, other substances or co-occurring conditions. Anxiety or low mood should be assessed rather than assumed to be caused by addiction alone.
Long-Term Impact Of Dihydrocodeine Addiction On Health
Long-term opioid use can cause persistent constipation, sedation, endocrine effects, tolerance, dependence and opioid-induced hyperalgesia, while overdose risk is strongly affected by dose, tolerance, health conditions and other sedatives. Liver risk may also come from combination products containing paracetamol; unsupported claims of inevitable organ damage should be avoided.
Opioid use disorder can coexist with anxiety, depression, trauma and other mental-health conditions, but causation varies. Integrated assessment and treatment can address both substance use and mental health without blaming the person.
Sedation, sleep disruption, pain, other medicines and substance use can affect concentration or memory. Persistent cognitive symptoms require clinical assessment rather than an assumption of irreversible decline.
How An Overdose Occurs
Overdose can follow dosing errors, reduced tolerance, non-medical use, unexpected product contents or combination with other sedatives. The central danger is respiratory depression: breathing becomes slow, shallow or stops, which can cause hypoxic injury, coma or death.
Alcohol, benzodiazepines, gabapentinoids, sleeping medicines and other opioids can add to sedation and respiratory depression. Combining them with dihydrocodeine can be fatal and requires specific clinical advice.
Symptoms Of Overdose And What To Do
Knowing the signs of a dihydrocodeine overdose can help to save lives. Key signs include:
- Extreme drowsiness, or inability to wake up
- Slowed or irregular breathing
- Blue or pale skin, especially around the lips or nails (from lack of oxygen)
- Pinpoint pupils
- Low blood pressure or weak pulse
- Reduced consciousness or inadequate response to stimuli.
If overdose is suspected, call 999 immediately, give naloxone if available, support breathing as instructed and stay with the person. Naloxone can temporarily reverse opioid effects, but repeat doses may be needed and its effect can wear off before dihydrocodeine does, so emergency assessment is still essential.
What Happens During Dihydrocodeine Withdrawal
Withdrawal can occur when a physically dependent person abruptly reduces or stops dihydrocodeine. Symptoms can be distressing, but severity varies. A clinician can help plan an individual reduction or opioid-use-disorder treatment without assuming that everyone requires the same setting.
The onset and duration of withdrawal vary with formulation, dose, duration of use, metabolism, health conditions and other substances. Symptoms can include:
- Sweating and chills
- Muscle aches and pains
- Nausea, vomiting and diarrhea.
- Restlessness and insomnia
- Rapid heart rate
Anxiety, irritability, restlessness and craving can accompany withdrawal. A return to use is not a personal failure; it signals a need to review medication, overdose prevention and continuing support because tolerance may have fallen.
How To Control Withdrawal Symptoms And Reduce Your Risk Of Relapse
Withdrawal management is only one part of care. In the UK, methadone or buprenorphine can be used as first-line opioid substitution treatment to reduce withdrawal and cravings and may be continued as maintenance treatment. The goal and duration should be agreed individually; treatment is not simply a smaller dose used to taper everyone off opioids.
Psychosocial support can complement medication by addressing goals, coping skills, relationships and co-occurring needs. Cognitive behavioral therapy, motivational approaches, peer support or family work may be offered according to preference and clinical need.
Available Treatment Programs for Dihydrocodeine Addiction
Treatment for opioid use disorder is available in community, outpatient, residential and inpatient settings. Placement should reflect symptom severity, overdose and withdrawal risk, physical and mental health, social circumstances, safety, accessibility and the person’s preferences.
Withdrawal Care and Medication: Detoxification is not a required first step before treatment. Methadone or buprenorphine can treat opioid dependence through stabilization followed by maintenance or an agreed withdrawal regimen. Care should include overdose prevention and continuing follow-up because withdrawal alone does not address ongoing opioid use disorder.
Residential or Inpatient Care: A structured setting may be appropriate when medical, psychiatric, social or safety needs cannot be managed adequately in outpatient care. Not every residential program provides 24-hour medical care, and treatment should not be presented as having a universal fixed duration.
Outpatient Treatment: Outpatient services allow a person to live at home while receiving scheduled care. They can provide medication for opioid use disorder, psychosocial treatment, physical and mental-health support and harm reduction; suitability depends on assessed needs, not a label of “mild” addiction.
Peer Support: Mutual-aid and peer-support groups can provide connection and shared experience for people who want them. They are optional and can complement, but should not replace, indicated medication or clinical care.
Overcoming Addiction: From Detox To Long-Term Recovery In The UK
Withdrawal management is not the endpoint of opioid-use-disorder treatment. Continuing medication, psychosocial support, overdose prevention and practical help can be adjusted over time. Follow-up should be planned before transitions in care, when overdose risk may increase.
Therapy and Counseling: No single therapy is best for everyone. Cognitive behavioral therapy, motivational approaches, group or family work and other supports may help when matched to the person’s goals, preferences and co-occurring needs.
Medication for Opioid Use Disorder: Methadone or buprenorphine can reduce withdrawal, craving, overdose and mortality risk and may be continued as long-term treatment. Medication does not require prior detoxification, and psychosocial support should be offered without making it a condition for access to indicated medication.
Return-to-Use and Overdose Prevention: Plans can identify high-risk situations, coping strategies, naloxone access and people or services to contact. If use resumes, continuing or re-entering care promptly is important because reduced tolerance increases overdose risk.
Ongoing Support Is Essential
Opioid use disorder can require continuing or intermittent care. Follow-up may include medication reviews, therapy, peer support, physical and mental-health care, housing or social support and naloxone planning. The frequency should be individualized, and goals should be defined with the person rather than framed around a single model of sobriety.
YOU MAY FIND THESE HELPFUL
A useful place to start.
Private Addiction Treatment & Rehab
ExploreUnderstandPrivate Opioid Addiction Treatment & Rehab
ExploreUnderstandDepression
ExploreAssessment & Treatment Planning
ExplorePlan your stayHow Admission Works
ExploreUnderstandPrivate Addiction Treatment & Rehab
ExploreEditorial evidence
Evidence & sources
Selected clinical guidelines, peer-reviewed research, and public-health sources used in this article.
View all 14 sourcesShow fewer sources
Clinical context
Clear information is framed around complex and co-occurring presentations.
Individual factors
Assessment remains essential because needs and risks differ from person to person.
Next steps
A confidential conversation can help clarify the most appropriate route forward.
Not sure where the situation fits?
Your admissions team
A confidential first conversation can help clarify the presentation and whether our setting is appropriate.